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Abstract: In cancer, proliferation of malignant cells is driven by 
overactivation of growth signaling mechanisms, such as the EGF-
EGFR pathway. Despite its therapeutic relevance, this extracellular 
protein-protein interaction (PPI) has remained elusive to inhibition by 
synthetic molecules, mostly due to its large size and lack of binding 
pockets and cavities. Designed peptides, featuring cyclic motifs and 
other structural constraints, have the potential to modulate such 
challenging PPIs. Here we present the structure-based design of a 
series of bicyclic constrained peptides that mimic an interface 
domain of EGFR and inhibit the EGF-EGFR interaction by targeting 
the smaller partner (EGF). This design process was guided by the 
integrated use of in silico methods and biophysical techniques, such 
as NMR and SAW. The best analogues were able to selectively 
reduce the viability of EGFR+ human cancer cells. In addition to their 
efficacy, these bicyclic peptides are endowed with exceptional 
stability and metabolic resistance—two features that make them 
suitable candidates for in vivo applications. 
Introduction 
Protein-protein interactions (PPIs) play a relevant role in all 
cellular processes. The selective modulation of PPIs has 
emerged as a new strategy for therapeutic intervention. PPIs are 
typically characterised by large, flat and featureless interfaces,[1] 
thereby complicating the use of conventional small-molecule 
drugs as inhibitors.[2] As an alternative, peptides have a higher 
degree of structural flexibility, which allows them to better adapt 
to irregular targets,[3] and they can be designed to display a 
variety of topologies that closely mimic the structural features 
found in PPIs.[4] However, peptides tend to have low serum 
stability and poor ability to cross physiological barriers.[5] In this 
regard, these limitations need to be addressed if in vivo 
applications of these molecules are to be pursued. 
 
At the onset of cancer, cells acquire the capacity to self-
proliferate through the uncontrolled production of molecules that 
promote cell growth and differentiation.[6] Among these, 
epidermal growth factor (EGF) has been shown to participate in 
many types of solid tumour, including head and neck, breast, 
colon, ovarian and non-small-cell lung cancer.[7][8] To perform its 
function, EGF binds with high affinity (KD = 1.9 nM)[9] to its 
membrane receptor (EGFR),[10] triggering intracellular events 
that lead to uncontrolled cell growth, tumour invasion and 
metastasis.[8] 
 
Therefore, the EGF-EGFR pathway has become a main focus 
for selective chemotherapeutic intervention and, as a result, two 
classes of EGFR inhibitors have been clinically approved, 
namely monoclonal antibodies[11] (cetuximab, panitumumab), 
which target the extracellular domain of EGFR, and small-
molecule kinase inhibitors[12] (gefitinib, erlotinib), which block the 
intracellular phosphorylation of the receptor. Despite impressive 
initial response rates to these drugs, most patients end up 
developing drug resistance—a major limitation that reduces the 
long-term efficacy of the therapy.[13] The overexpression of EGF 
and/or EGFR, as well as activating mutations on the receptor, 
have been shown to underlie the main drug resistance 
mechanisms.[8] Thus, novel approaches to block the EGF-EGFR 
pathway and targeted combination therapies are in high demand. 
 
In this regard, the direct inhibition of EGF is considered a 
promising strategy.[14] Although similar growth factors (such as 
VEGF) have been successfully addressed using this 
approach,[15] no current drugs are able to specifically target 
EGF.[7] However, we recently showed that peptides represent a 
significant step in this direction.[16] Herein, we present the 
structure-based design of bicyclic-constrained peptides that 
adopt a well-defined structure and mimic one of the interacting 
domains of EGFR. In this process, computational and 
biophysical methods were used as complementary approaches 
to guide the design of more stable and active analogues. In 
addition to studying their interaction with EGF at the molecular 
level, we confirmed their potential to block the EGF-EGFR 
interaction in a specific receptor-ligand assay and also in human 
carcinoma cells, which constitutively overexpress EGFR. Finally, 
the stability of the best designs was validated in biologically 
aggressive media, such as serum and liver hepatocytes, thereby 
confirming the feasibility of our lead compounds for further in 
vivo application. 
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Results and Discussion 
Design and biophysical evaluation of peptide ligands 
 
The binding of EGF to EGFR occurs through a large (1440 Å2) 
and complex interface, in which various domains of the receptor 
are involved. Nevertheless, a number of hotspots are found on 
residues 7 to 34 of the receptor (Figure 1A). In particular, 
residues 16–18 of EGFR and residues 31–33 of EGF form a 
short parallel β-sheet, stabilised by backbone hydrogen bonds. 
Also, the α-helical motif in this EGFR domain features several 
hotspots (Asp22, Leu25, Arg29) that establish key contacts with 
EGF. As we recently reported, a cyclic peptide (cp28) 
comprising this EGFR region was able to recapitulate the 
binding of the receptor to EGF (KD = 286 µM).[16] However, the 
large size and hydrophobic character of this peptide, in addition 
to its all-L composition, translated into poor solubility and 
biological stability, thus limiting its in vivo application and 
potential development as a drug candidate. 
 
Using a rational design approach, our goal was to mimic the 
bioactive conformation of the receptor with constrained peptides, 
which are endowed with superior stability and drug-like 
properties.[17] Initially, we designed three peptides (named 
cp23A, B and C, Figure 1B and C), each with a turn-inducing D-
Pro-Gly motif that replaced part of the long cp28 loop. This loop 
plays a structural role in EGFR but is not directly involved in 
interactions with EGF. In addition, we conservatively mutated 
the Phe residues at the helix for Tyr, in order to improve the 
overall water solubility of the construct. Finally, peptides cp23B 
and C bore a second cyclic constraint, in the form of a disulphide 
bridge, which aimed to restrain the flexibility of the peptide loop. 
In these last designs, we inspected the peptide sequence for 
side chains that would allow the introduction of a disulphide 
crosslink, without altering the overall conformation of the peptide. 
In cp23B, Asn6 and Leu11 were replaced by L-homocysteine 
and L-Cys, respectively. Alternatively, in cp23C, Gln10 and 
His17 were modified by a D- and L-configured building blocks 
(Figure 1C). 
 
The synthesis of the bicyclic scaffolds was achieved using the 
native chemical ligation strategy (Figure S1). This approach 
involves Fmoc-based solid-phase peptide synthesis (SPPS) of 
linear peptides featuring a C-terminal N-acylurea moiety, which 
acts as thioester precursor during the ligation. Treatment of the 
unprotected peptide in solution with a thiol additive (4-
mercaptophenol) then catalyses in situ the intramolecular 
ligation, forming the head-to-tail cyclic peptides in under an hour 
at pH 7 (see the Experimental Section for details). Finally, the 
thiol groups are readily oxidised to yield the desired bicyclic 
peptides. 
 
The circular dichroism (CD) spectra of monocyclic cp23A and 
bicyclic cp23B (Figure 1D) showed a negative band at ca. 208 
A) 
D) 
B) C) 
E) 
Figure 1. A) Detail of the EGF-EGFR binding interface (EGF on green surface; EGFR in grey cartoon, the relevant residues 7-34 are highlighted in red; 
adapted from PDB 1ivo). B) Main modifications performed on the structure of the EGFR-derived peptide cp28. C) Sequence and cyclic constraints of peptide 
analogues cp23A-C (X = L-homocysteine). Residues are coloured according to their physicochemical nature: blue, polar; grey, hydrophobic; orange, 
aromatic; purple, basic; red, acidic; yellow, SH-residues; green, Gly. D) CD spectra of cp23A-C in phosphate buffer (pH 6.8, 10% TFE). E) Average CSPs 
induced by peptides cp23A, cp23B (reduced and oxidised) and cp23C on various EGF residues. 
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nm and a second minimum at ca. 222 nm, thereby indicating a 
prominent content of α-helix, a motif that is crucial for the PPI. In 
contrast, the alternative bicyclic topology that we tested in 
cp23C had a strongly reduced helical content. 
 
Several biophysical methods were used to assess the binding of 
the peptides to EGF. First, the effects of the interaction were 
evaluated in the 15N-1H HSQC spectra of a uniformly labelled 
15N-EGF sample. Comparison of the average chemical shift 
perturbations (CSPs) induced by the three analogues revealed 
larger perturbations for cp23B than for cp23A and cp23C 
(Figure 1E). Notably, the oxidised cp23B caused greater 
changes in the protein signals than its reduced form. The most 
significant perturbations occurred on residues on the A- and B-
loops of EGF (L8, S9, G12, H16-V19), which are involved in the 
EGF-EGFR interaction (Figure 2A). 
 
To evaluate the strength of the peptide-EGF interactions, we 
used a surface acoustic wave (SAW) biosensor assay.[18] EGF 
was covalently immobilised on the gold surface of the chip and 
binding events occurring on this functionalised surface, which 
directly affect the acoustic wave parameters of the biosensor, 
were measured. In this assay, the bicyclic peptide cp23B 
displayed the best affinity of the series (KD = 575 µM, Figure 2A 
and Table 1), consistent with the changes observed in the NMR 
spectra of EGF. As shown by these results, the helical motif is a 
required element for stabilising the entire peptide backbone. The 
bicyclic architecture of cp23B—but not of cp23C—further 
constrains the peptide and enables the folding of the loop in the 
bioactive conformation. 
 
Having proved that we could retain the main requisites for 
binding in a smaller, more rigid, and synthetically accessible 
scaffold, we used computational methods to enhance the folding 
(in terms of resemblance to the EGFR bioactive conformation) 
and binding affinity of the peptides. Compared to docking 
methods, which treat the protein as a rigid or semi-rigid body 
and are not convenient for flexible proteins such as EGF, 
molecular dynamics (MD) simulations are able to extensively 
sample the interacting complex in a solution environment. We 
subjected the cp23B-EGF complex to free MD simulation and, 
from regular snapshots taken during the first part of the 
simulation, we calculated the theoretical mean free energy of 
binding (ΔG = -31.4 kcal/mol, according to the MM/GBSA 
method). In the last part of the simulation, larger fluctuations 
occurred on the peptide backbone, causing its dissociation from 
EGF (Figure S2). 
 
We then performed virtual mutations on the weaker points—from 
a design point of view—of the cp23B sequence. For instance, 
several replacement options were tested for Met22, as oxidation 
of its side chain often occurred during experimental 
manipulation. Also, we explored the introduction of a second Pro 
residue at the N-terminus of the α-helix, with the aim to stabilise 
this structural motif. In total, we generated and evaluated in 
silico 28 new peptide structures (Table S1). As revealed by the 
calculated ΔG values, in most cases the Y→P mutation 
produced an 8-10 kcal/mol gain of interaction energy, especially 
when Pro was at the 12th position. This observation confirms the 
stabilizing effect of Pro as N-cap for the helix,[19] which translated 
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Figure 2. Amino acid sequences of peptides cp23B (A), cp23F (B) and cp23G (C) (X = L-homocysteine, Z = L-norvaline). For each, a representative region 
of the 15N-1H HSQC spectra of EGF is shown, in the absence (blue) and presence (red) of ligand (1 mM). Below, the SAW sensorgram at a range of 
concentrations and the calculated KD values for the interaction with EGF are shown for each peptide. 
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into less backbone fluctuations and improved peptide-EGF 
contacts during the MD (Figure S2). Also, a conservative 
M22Nva mutation (as in cp23E and F) was suitable for replacing 
the unstable side chain of this Met residue. 
 
To test the new computational designs, we selected three of the 
best analogues, namely cp23D, cp23E and cp23F, for chemical 
synthesis and evaluation (Table 1). NMR revealed that all three 
peptides produce clear CSPs on the same part of the protein (L8, 
S9, G12, H16-V19) as cp23B, thus confirming the same mode 
of binding (Figure 2B). In the quantitative SAW experiment, the 
interaction of cp23F produced well-defined association and 
dissociation curves, which translated into a higher affinity (KD = 
279 µM) than cp23B. In contrast, the sensorgrams for both 
cp23D and cp23E were low-intensity and imprecise, thus 
indicating loss of affinity (Figure S4). These observations 
suggest that the introduction of radical modifications on the 
peptide sequence, as in these last designs, impair binding to 
EGF. 
 
Given the abovementioned results, we implemented a final cycle 
of computational modelling for the further optimisation of cp23F. 
To this end, we generated a set of heterochiral mutants by 
introducing L- and D-amino acids in suitable positions of the 
sequence. Not surprisingly, most new mutations had a 
detrimental effect on the ΔG (Table S2). Nevertheless, the 
substitution of Gly10 for large apolar residues, such as Met (as 
in cp23H) or Tyr, formed new hydrophobic contacts with the B-
loop of EGF (Val29, Val30), thus improving the ΔG score. The 
introduction of D-amino acids in position 2 of the sequence also 
led to theoretically stronger interactions, with the T2r mutant 
(cp23G) having the lowest MM/PBSA score of the entire set 
(-8.1 kcal/mol). As seen in the MD simulation, the guanidine 
group of the D-Arg formed a highly stable salt bridge with Asp42 
in the C-loop of EGF (Figure S2), and enhanced the hydrophilic 
character of the peptide. 
 
Experimentally, the affinities of cp23G (KD = 252 µM) and 
cp23H (KD = 115 µM), as measured by SAW, were superior to 
that of cp23F, although not proportionally to the predicted ΔG 
values (Figure 2C and Table 1). The induced shifts on the 15N-1H 
HSQC spectra of the protein confirmed their binding to the 
EGFR-binding epitope of EGF. However, the poor solubility of 
cp23H prompted us to select cp23G for further studies. 
 
Table 1. Sequence of all cp23 analogues. For cp23B analogues, the ΔG 
values are shown, using either PB or GB solvation methods. 
D) 
B) 
A) 
C) 
Figure 3. A) Replica exchange MD experiments show the most populated conformations for peptides cp23B, cp23F and cp23G (in blue) superimposed with 
the EGFR bioactive conformation (in green). RMSD values calculated for the peptide backbone. B) CD spectra of cp23G in phosphate buffer (pH 6.8, 10% 
TFE) at temperatures ranging from 4 to 84ºC. C) Chemical shift deviations of cp23G 1Hα (top) and 13Cα (bottom) from random coil values. D) NMR-derived 
low-energy averaged structure of cp23G. The α-helical motif and the disulphide bond are shown in red and yellow, respectively. 
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Analogue Sequence[a] 
MM/GBSA 
(kcal/mol) 
MM/PBSA 
(kcal/mol) 
KD 
(µM)[b] 
cp23A 
&GTSNKLTQLGTYEDH
YLSLQRMp& 
- - 773 
cp23B 
&GTSXKLTQCGTYEDH
YLSLQRMp& 
-31.4 6.8 575 
cp23C 
&GTSNKLTcLGTYEDXY
LSLQRMp& 
- - 1860 
cp23D 
&GTSXKLTQCGTPADD
AASAARMp& 
-46.8 -12.7 1420 
cp23E 
&GTSXAETQCGTPEDH
YLSLQRZp& 
-46.6 -9.2 >2000 
cp23F 
&GTSXKLTQCGTPEDH
YLSLQRZp& 
-42.1 -2.9 280 
cp23G 
&GrSXKLTQCGTPEDHY
LSLQRZp& 
-41.4 -8.1 252 
cp23H 
&GTSXKLTQCMTPEDH
YLSLQRZp& 
-48.1 -6.0 115 
[a]X = L-homocysteine, Z = L-norvaline. Residues forming disulphide bonds 
are underlined. [b]Affinity values obtained by SAW. 
 
Structural characterisation of the bicyclic peptides 
 
To gain a molecular-level understanding of the differences 
between these analogues, we simulated their minimal energy 
structures by replica exchange MD (Figure 3A). Compared to 
cp23B, the helical domain in cp23F was better structured and 
more stable, thanks to the constraining effect of the Pro residue 
in position 12. Nevertheless, backbone RMSDs of about 5 Å 
(compared to the bioactive conformation, PDB 1ivo) were 
obtained for both analogues, due to the poor folding of the 
flexible loop of the peptide. The new D-Arg mutation in cp23G 
partly solved this problem. Indeed, a close inspection of its 
lowest energy structure showed how the hydrocarbon part of the 
Arg side chain fills the empty space at the central cavity of the 
peptide, thus preventing the collapse of the flexible loop. Overall, 
this renders a conformation that closely mimics that of EGFR 
(RMSD = 2.7 Å). 
 
To confirm the computational predictions, we investigated the 
structural characteristics of cp23G in solution. First, we 
performed CD spectroscopy of the peptide at a range of 
temperatures (Figure 3B). The CD spectra at 25ºC showed two 
negative bands at ca. 208 and 222 nm, thereby confirming the 
existence of the α-helical motif. Notably, when the sample was 
heated to 84ºC, the CD spectrum was nearly identical to the 
former, which reveals a high conformational rigidity for cp23G, 
given its small size. Second, we performed NMR measurements 
of the peptide in a buffered aqueous solution at pH 6.8. The 1HN 
backbone chemical shifts exhibited a relatively large dispersion, 
which is typical of a more rigid and defined structure (Figure S7). 
The secondary chemical shifts of both 1Hα and 13Cα showed 
consecutive deviations from random coil values,[20] negative for 
Hα and positive for Cα, along the Pro12-Gln20 region, indicative 
of α-helix conformation (Figure 3C). This hypothesis was further 
confirmed by the presence of short- and medium-range NOEs in 
this part of the sequence (Figure S7). Using these experimental 
constraints, we modelled a 3D-structure of cp23G in solution 
(Figure 3D), which resulted very similar to that of the previous 
replica exchange simulation (RMSD = 1.8 Å). This structure 
exhibits the features that have been key in this design process, 
namely precise folding of the peptide backbone, which is 
stabilised by the α-helix and the intramolecular disulphide bridge. 
 
PPI inhibition assays 
To produce a biological outcome, peptides binding to EGF must 
disrupt the interaction with its receptor. Therefore, they must 
compete with the very strong affinities that naturally govern this 
process. On the other hand, such molecules benefit from acting 
on the extracellular space, where higher effective concentrations 
can be reached. We first assessed the capacity of our peptides 
to inhibit the EGF-EGFR interaction in an AlphaScreen bead-
based assay, which mimics the protein setting found in cells. For 
all the designs, a concentration-dependent inhibition of the EGF-
EGFR interaction was observed (Figure 4A and S8). The cp23G 
peptide was the most potent inhibitor of the series (IC50 = 149 
µM), an effect that correlates with the binding affinities obtained 
by SAW. 
 
We next evaluated the effect of our peptides on the viability of A-
431 cells, which represent a particular subtype of skin carcinoma, 
characterised by abnormally high expression levels of EGFR. 
Cell viability was measured by XTT after a 72-h incubation with 
EGF-containing media and a range of inhibitor concentrations. 
To validate the assay conditions, erlotinib was used as positive 
control (IC50 = 2.9 µM). Under these conditions, cp23G had the 
greatest inhibitory effect (IC50 = 24 µM, Figure 4B), in the same 
range as cp28 (IC50 = 30 µM). Consistent with the previous 
results, cp23B and cp23F were not able to fully block cell 
proliferation (Figure S9). To confirm that the inhibitory effect was 
specific for the EGFR pathway, a parallel assay was performed 
on two EGFR-independent cells, namely MCF7 (a breast cancer 
line that overexpresses oestrogen receptor, but normal levels of 
EGFR) and healthy fibroblasts. In both lines, lack of toxicity was 
observed for all the peptides tested (Figure 4B and S9), a result 
that is in agreement with the principle of targeted chemotherapy. 
 
Stability studies in biological media 
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One of the main challenges faced by therapeutic peptides is that 
they typically present short half-life in serum, rapid clearance 
from circulation, and poor tissue distribution.  Being an all L-
peptide, our first EGF-EGFR inhibitor cp28 was predictably 
labile in vivo. In fact, in human serum, cp28 showed a half-life of 
89 min, which is reasonable for a natural peptide (the half-life of 
a linear peptide is typically less than 30 min).[21] To identify the 
main cleavage sites on the sequence of cp28, we performed 
MS/MS analysis of the serum sample after 2 h of incubation. 
Interestingly, the three main metabolites resulted from hydrolysis 
and/or oxidation of Arg23 and Met24 (Figure S10), a region in 
which the peptide chain adopts a rather extended conformation 
and is thus more accessible to the active site of proteolytic 
enzymes. 
 
On the contrary, the new bicyclic analogues, which present a 
more constrained structure and no free N- and C-terminal ends, 
were expected to present greater resistance to proteolytic 
degradation. To validate this hypothesis, we analysed the 
concentration of peptides in human serum at 37ºC for 24 h. 
Remarkably, no degradation was appreciated after 8 h, and 
cp23F and cp23G remained more than 60% unaltered after 24 h 
(Figure 4C). In these peptides, norvaline replaces the more 
vulnerable Met24 and this region is further protected from 
hydrolysis by an artificial D-Pro-Gly motif adjacent to it. 
 
The greater stability of the bicyclic peptides was further 
confirmed in human hepatic microsomes, which represent a 
more aggressive environment than the serum.  Indeed, liver 
microsomes contain a diversity of metabolising enzymes, such 
as proteases, oxidases, dehydrogenases and acyl-/alkyl-
transferases, all of which contribute to peptide metabolism, 
especially in hydrophobic sequences. Experimentally, the 
bicyclic cp23 analogues, cp23G in particular, showed 
significantly lower clearance values than cp28 (Figure 4D), a 
metric that correlates with the in vivo metabolic clearance.[22] 
The difference in stability can be explained not only by the 
presence of unnatural residues, which hamper the recognition of 
enzymes, but also by the lower hydrophobicity of cp23G. As a 
result, the structural modifications introduced in this new bicyclic 
design not only guarantee the target affinity and cellular 
efficacy—already shown in the first cyclic inhibitor—but add 
relevant features such as increased solubility and superior 
biostability. 
Conclusions 
The EGF-EGFR interaction involves the formation of high-affinity 
dimeric complexes—mediated by several discontinuous 
epitopes—which extend along a large and irregular binding 
interface. Due to these challenging features, this PPI has been 
successfully targeted only using antibodies, such as cetuximab, 
which currently provide the main chemotherapeutic approach in 
several types of cancer. However, poor bioavailability and the 
development of acquired drug resistance reduce the long-term 
success of antibody-based therapies. Designed peptides have 
emerged as a new class of therapeutics that combine the 
surface recognition properties of antibodies and the 
pharmacological behaviour of small molecules. 
 
Using computational algorithms and biophysical techniques, we 
have implemented a rational and iterative process that has 
allowed the generation of a series of bicyclic constrained 
peptides that mimic the bioactive conformation of EGFR upon 
binding to EGF. The binding of these molecules to EGF has 
been quantified by SAW and characterised by NMR, and their 
inhibitory effect on the EGF-EGFR interaction has been 
C) 
A) 
B) 
D) 
Figure 4. A) EGF-EGFR inhibition (AlphaScreen assay) at a range of cp23G concentrations. B) Viability of A-431 cells (overexpressing EGFR), MCF-7 cells 
(normal EGFR levels) and healthy J2P fibroblasts, incubated at a range of cp23G concentrations. C) Stability of the peptides in human serum at 37ºC (the 
linear peptide ACP was used as control, in brown triangles). D) Metabolic stability in human hepatic microsomes (propranolol was used as control). In all 
cases, experiments were performed in triplicate, and error bars represent the SD. 
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confirmed in a specific PPI-disruption assay. Moreover, these 
peptides selectively decrease the viability of human cancer cells 
overexpressing EGFR, with mid-micromolar IC50 values—only 
one order of magnitude higher than the FDA-approved inhibitor 
erlotinib. Although weak affinities are sometimes considered a 
handicap, they are not an exception for PPI inhibition and 
provide the opportunity to selectively target biomarkers (like 
EGFR) that are overexpressed in cancer cells but also present 
in most healthy tissues, thus reducing toxicity. Indeed, as a 
result of the harmful effects of chemotherapy, there is renewed 
interest in the use of weak binders, especially as part of a 
multivalent strategy.[23] All in all, the efficacy of these peptides, 
added to their exceptional stability in biological media, support 
their use as complementary compounds in multidrug cancer 
therapy. 
Experimental Section 
Materials: All amino acids, resins, solvents and reagents were 
purchased from Bachem AG (Bubendorf, Switzerland), Iris Biotech 
(Marktredwitz, Germany), Scharlab (Barcelona, Spain), Sigma-Aldrich 
(Milwaukee, WI), GL Biochem Shangai Ltd. (Shangai, China), and Fluka 
Chemika (Buchs, Switzerland). The human carcinoma (A-431) and 
breast cancer (MCF7) cell lines were acquired from American Type 
Culture Collection (Manassas, VA). The fibroblast cell line (J2P) was 
kindly provided by L. Rinaldi (IRB Barcelona). The medium used for cell 
culture was Dulbecco’s Modified Eagle’s Medium (DMEM)-high glucose, 
obtained from Sigma-Aldrich. General material (sterile and not sterile) 
was acquired from Sharlab (Barcelona, Spain) and Deltalab. 
Molecular dynamics and ΔG calculations: Coordinates for EGF and 
cp28 (residues 7 to 34) were extracted from the Protein Data Bank (PDB 
ID: 1ivo). For the bicyclic analogues, the peptide structure was manually 
modified and the local clashes were relieved by performing a short 
minimization. The Amber Parm99SB force field was used; the Leap 
module of the AMBER package was used to immerse the EGF-peptide 
complex in a pre-equilibrated octahedral box of TIP3P water molecules. 
Chlorine or sodium ions were added to obtain an electrostatically neutral 
system. The initial complex structure was first subjected to a minimization 
protocol consisting of 1000 steps of steepest decent method followed by 
500 steps of conjugate gradient method. Thermalization of the system 
was performed in the NVT ensemble during 200 ps, using a time step of 
1fs and increasing the temperature from 100 to 298 K, where a force 
constant of 5 kcal mol-1 Å-2 was applied to protein backbone atoms. Prior 
to the production run, a short MD simulation (100 ps) in the NPT 
ensemble was done in order to equilibrate the system density to 1 atm 
and 298 K. The simulations were carried out at constant pressure (1 atm) 
and temperature (298 K) for 20 ns, except for some peptides that were 
extended to 50 ns. Low harmonic constraints (2 kcal mol-1 Å-2) were used 
to reduce the protein mobility. Constant temperature was achieved using 
the Langevin thermostat with a collision frequency of 2 ps-1. The SHAKE 
algorithm was used to keep bonds involving hydrogen atoms at their 
equilibrium length. The particle-mesh Ewald summation method was 
used to deal with long range electrostatic interactions and a cut-off of 10 
Å was applied for non-bonded interactions. The simulations were 
conducted with the PMEMD module of the AMBER 14 program. The 
trajectories were analysed using frames collected every 2 ps during the 
production runs. 
From the collected MD trajectories, the molecular mechanics Poisson-
Boltzmann surface area (MM/PBSA) and Generalized Born (MM/GBSA) 
methods were used to compute the free energy of binding (ΔG) between 
the peptides and EGF. A numerical solution of the Poisson-Boltzmann 
equation,[24] implemented in AMBER, was used to calculate the polar part 
of the solvation free energy, using a low (ε = 1) and high-dielectric 
medium (ε = 80) for the solute and solvent, respectively. The solute-
solvent interface was defined by the solvent-excluded molecular surface, 
where a solvent probe radius of 1.4 Å was employed. The non-polar 
contribution to the solvation was estimated from the solvent-accessible 
surface area[25] using the default scaling factor in Amber (γ = 0.0072 kcal 
mol-1 Å-2). The less computationally demanding MM/GBSA approach was 
also computed using analogous parameters.[26] The reported values of 
MM/GBSA and MM/PBSA were computed for a subset of 500 equally 
spaced snapshots along the converged part of each simulation, when 
both ligand and protein reached a stable interaction state. 
Replica exchange MD: To assess the structure of the peptides in 
solution, replica exchange molecular dynamics (REMD) was performed. 
The initial structure (identical to the one used in the MD simulation 
described above) was first subjected to minimization protocol consisting 
of 1000 steps of steep decent method followed by 500 steps of conjugate 
gradient method. The optimized structure was gradually heated to 300 K 
in 200 ps. The final structure was chosen as the initial structure for all the 
16 replicas in REMD simulations. Temperatures were set in a range from 
300 to 600 K with an exchange probability of 30%.[27] Generalized Born 
model with an effective salt concentration of 0.2 M was deployed to 
mimic the solvation effect. Nonpolar solvation term was approximately 
represented by surface area term.[28] Integral time step was set to 1 fs. 
Temperature was regulated using Berendsen thermostat with a coupling 
time constant of 1 ps. SHAKE algorithm was used to constrain all the 
covalent bonds involving hydrogen atoms. Swaps were attempted every 
2 ps and MD simulations were extended to 200 ns for each replica. 
Solid-phase peptide synthesis: All bicyclic peptides were synthesized 
on Dawson Dbz AM resin with a substitution of 0.4-0.5 mmol/g. The first 
amino acid was manually coupled. The N-Fmoc-protected amino acid (3 
equiv) was preactivated with HATU (3 equiv) and DIPEA (3 equiv) in the 
minimal volume of DMF and was added to the resin. The mixture was 
allowed to react in an orbital shaker with stirring for 30 min. Then, peptide 
chains were elongated on a CEM Liberty Blue microwave peptide 
synthesizer. Fmoc deprotection was carried out using 10% (w/v) 
piperazine and 0.1 M OxymaPure in a 9:1 mixture of NMP and EtOH. 
The N-Fmoc-protected amino acids (5 equiv, 0.2 M in DMF) were added 
with OxymaPure (5 equiv, 1 M in DMF) and DIC (5 equiv, 0.5 M in DMF) 
to the resin. The mixtures were stirred for 3 min at 90ºC, except for 
cysteines, histidines and arginines, which were coupled at 50ºC for 10 
min. The N-terminal residue was introduced using a Boc-amino acid. 
After chain elongation, the resin was washed extensively with DMF and 
of 1,2-dichloroethane. 4-nitrophenyl chloroformate was dissolved in the 
least amount of 1,2-dichloroethane, added to the resin and left to gently 
agitate for 1 h at room temperature. The resin was washed with DCM 
and DMF, and reacted for 30 min with a 0.5 M solution of DIPEA in 
anhydrous DMF. Finally, peptides were cleaved with concomitant 
removal of the side-chain protecting groups, using TFA, H2O and TIS 
(92.5:5:2.5). 
Native chemical ligation: The ligation buffer (6M guanidinium 
hydrochloride, 200 mM sodium phosphate, 20 mM TCEP, 100 mM 4-
mercaptophenol, pH 7) was freshly prepared and bubbled with nitrogen. 
The peptide was dissolved at a 2-3 mM concentration and the solution 
was stirred at rt for 4 h. Then, the reaction was acidified, extracted with 
TBME (2 x 50 mL) and loaded on a PoraPakTM C18 Cartridge for 
desalting. The guanidinium salts were washed with buffer, while the 
peptide was eluted at the end in H2O/ACN (1:1) and freeze-dried. To 
yield the final bicylic peptides, intramolecular disulfide bonds were 
formed under highly diluted conditions (20-40 µM), by stirring an aqueous 
solution of the peptides (pH 8) under air oxygen for 24 h. Peptides were 
purified by semi-preparative HPLC on a Waters 2700 sample manager 
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equipped with a Waters 2487 dual-wavelength absorbance detector, a 
Waters 600 controller, a Waters fraction collector and Masslynx software 
by using a Sunfire C18 column (150 x 10 mm x 3.5 μm, 100 Å, Waters), 
flow rate 6.6 mL/min, solvent A=0.1% trifluoroacetic acid in water; solvent 
B=0.1% trifluoroacetic acid in acetonitrile. 
Circular dichroism: Circular dichroism spectra were recorded using a 
Jasco 810 UV-Vis spectropolarimeter, equipped with a CDF 426S/426L 
peltier. Peptide samples were dissolved in NMR buffer (20 mM sodium 
phosphate, 50 mM NaCl, 0.1% NaN3, pH 6.8), and spectra were 
recorded at concentrations of 20 and 100 μM . A third reading was done 
after adding 10% trifluoroethanol (TFE) to the sample. The following 
parameters were used: sensitivity (standard, 100 mdeg), start (260 nm), 
end (190 nm), data pitch, (0.5 nm), scanning mode (continuous), 
scanning speed (200 nm/min), response (1 s), band width (1.0 nm), and 
accumulation (3). A blank spectrum of the buffer was substracted from all 
recordings, and the resulting spectra were smoothed using the Savitzky-
Golay method (convolution width = 21) and taken to zero at the far-UV 
region (λ = 260 nm). 
Recombinant human EGF expression: The nucleotide sequence 
encoding hEGF was cloned into a pOPIN vector[29] as a SUMO fusion 
protein, which also included a N-terminal His-tag and a SUMO protease 
cleavage site. This construct produced higher yields (2 mg/L) than the 
previously reported thioredoxin fusion system.[16] Cell transformation, cell 
growth, protein expression and purification were performed by following 
the standard protocol.[16] Uniformly labelled 15N-EGF was obtained by 
growing the E. coli cells in M9 minimal medium containing 15NH4Cl as the 
sole nitrogen source. 
NMR spectroscopy: 15N-labelled EGF was prepared in NMR buffer (20 
mM sodium phosphate, 50 mM NaCl, 0.1% NaN3, pH 6.8) supplemented 
with 10% D2O for a final sample volume of 180 μL, and fixed 
concentrations of protein (50 µM) and peptide (1 mM). 15N–1H HSQC 
spectra were recorded at 25ºC using a Bruker 600 MHz NMR 
spectrometer equipped with a cryogenic probe. Spectra were acquired 
with 128x2048 complex points with a total of 8 transients per increment. 
The x-carrier frequency was referenced to internal DSS-d6. Data 
processing was performed using TopSpin3.0. The quality of the protein 
sample was first evaluated by performing a 15N–1H HSQC spectrum of 
EGF, and comparing the results with the reported data.[30] Combined NH 
chemical shift perturbations (CSP = [(δN/5)2 + (δH)2]½ were plotted for 
each protein residue; only CSPs > (mean + SD) were considered 
significant. 
For the structural analysis of cp23G, the peptide was dissolved in NMR 
buffer supplemented with 10% trifluoroethanol and 10% D2O for a final 
sample volume of 350 μL. Residue specific assignments were obtained 
from 2D total correlated spectroscopy (TOCSY),[31] while 2D nuclear  
Overhauser effect spectroscopy (NOESY)[32] permitted sequence specific 
assignments. 13C resonances were assigned from 2D 13C–1H HSQC 
spectra. The TOCSY and NOESY mixing times were 70 and 200 ms, 
respectively. The D1 relaxation delay was 1.5 s. 
Simulated annealing protocol: main NOEs among peptide residues 
(Tyr16-Glu13, Arg2-Leu19, Arg21-Leu17, Gln20-Tyr16, His15-Gln8) were 
deployed through a set of 500 independent simulated annealing MD 
simulations where NMR restraints were applied by using the Sander 
module in conjunction with the AMBER99 force field. The most populated 
conformation in the REMD was used as the starting structure in each 
annealing simulation. The generalized Born implicit solvent model with an 
effective salt concentration of 0.2M was applied. A total of 100 ps of MD 
were run with a 1 fs time step. A long-range cutoff of 10.0 Å was used for 
non-bonded interactions. The upper and lower distance Cα- Cα atom 
restraint limits were set to 10.0 and 4.5 Å, respectively, to sample a a 
broader conformational according to NOE data, with a force constant of 
10.0 kcal mol-1 Å-2. Chirality restraints (50.0 kcal mol-1 Å-2) were used to 
avoid chirality flipping at high temperatures in the simulated annealing 
protocol. Temperature was increased to 700 K in the former 20 ps of 
simulation to be then gradually cooled down to 300K in the remaining 
simulation time. Different seed numbers were used in each simulation. 
For each independent simulation, the lowest AMBER energy structure 
conformation was selected as representative of the conformational space 
explored. The 500 simulated annealing conformations were finally 
clustered using Ptraj module to obtain the low-energy averaged structure 
compatible with NMR data. 
SAW biosensor: Affinity analyses were performed with a Sam5 Blue 
biosensor (SAW Instruments, Bonn, Germany). The chip surface was 
functionalized with EGF following the reported protocol,[16] and peptides 
were injected at a range of micromolar concentrations selected to cover 
the binding equilibrium constant. Sensorgrams were analysed using the 
Origin Pro 7.5 and FitMaster software. Briefly, the signal at the 
association equilibrium were represented for each ligand concentration, 
and non-linear fitting of the data was performed to obtain the KD values of 
the interaction. 
AlphaScreen assays: 10 µL of EGF (His-tag functionalized, 3 nM final 
concentration in PBS buffer, 0.1% BSA, 0.1% Tween-20, pH 7.4) and 10 
µL of peptide (at different concentrations) were added to 96-well 
Optiplates (PerkinElmer) and incubated at rt for 15 min. EGFR-Fc (3 nM 
final concentration in the same buffer) was then added and incubated for 
30 min. Next, 10 µL of Protein A 3835 Donor beads (20 µg/mL final 
concentration, 60 min incubation) and anti-His acceptor beads (10 µL, 20 
µg/mL final concentration) were added. After 30 min incubation, the 
fluorescence emission was recorded at 615 nm in an EnVision Multilabel 
Reader. Dose-response curves were obtained with the GraphPad Prism 
6.03 software, using a non-linear fit and variable slope, from which IC50 
values were calculated. 
Cell viability assay (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophen-
yl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium [XTT]): A-431 human 
cancer cells (2.5 x 106 EGFR/cell)[33] were seeded in a 96-well Corning 
microplates (2 x 103 cells/well). After 24 h of incubation at 37ºC, cells 
were treated with the peptides dissolved in Dulbecco’s Modified Eagle’s 
Medium (high glucose, 10% FBS containing EGF and growth factors) for 
72 h (100 µL, concentration range 0.5-150 µM). Then, the peptide 
solution was removed and substituted with fresh medium. 50 µL of 
activated-XTT solution (0.1 mL of the activation reagent in 5.0 mL of the 
XTT reagent, mixed 15 min before use) was added to each well and 
incubate for 4 h at 37ºC.  The absorbance at 450 nm was measured in a 
PowerWave X reader (Bio-Tek, INC), where the positive control was cells 
treated with DMSO and the negative control was untreated cells. Each 
experiment was performed in triplicate, and the IC50 was calculated by 
linear regression fitting (concentration vs. response curve) using 
GraphPad Prism. The same conditions were used for studying MCF7 and 
J2P fibroblast viability. 
Stability in human serum: Peptides at a final concentration of 150 μM 
were dissolved in Hank's balanced salt solution and incubated at 37ºC in 
the presence of 90% human serum during 24 h. Then, 50 μL aliquots 
were extracted at different incubation times and treated with 200 μL of 
MeOH to precipitate serum proteins. After 30 min centrifugation at 4ºC, 
the supernatant was filtered and analysed by HPLC to calculate the 
percentage of intact peptide in the sample. The linear peptide ACP was 
used as positive control. 
Metabolic stability in human microsomes: Peptides were dissolved in 
water (713 μL, 1 μM final concentration) and potassium phosphate (200 
μL, 0.5 M, pH 7.4), NADPH regenerating system solution A (50 μL) and 
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NADPH regenerating system solution B (10 μL) were added. This mixture 
was warmed to 37°C for 5 minutes. Then, human liver microsomes (25 
μL, 0.5 mg) were added. The mixture was immediately vortexed and 
incubated at 37°C with orbital agitation (100 rpm). 100 μL aliquots were 
taken at 0, 5, 10, 20, 30, 40, 50 and 60 minutes, and treated with 100 μL 
of ACN to precipitate serum proteins. The extracted samples were 
centrifuged and analysed by UPLC-MS. 
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